DUR Board Overview
The Mississippi Division of Medicaid’s Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for providers and beneficiaries. The DUR Board is composed of twelve participating Medicaid providers who are in good standing with their representative organizations.
The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.
DUR Board Meeting Information
The Drug Utilization Review (DUR) Board meets quarterly. Meetings are scheduled for room 145 at 1 p.m. in the Woolfolk Building, 501 North West Street, Jackson, MS. The DUR meeting dates for 2020 are as follows:
March 19, June 11, September 17, and December 3, 2020
DUR Board Meeting Resources
DUR Board Information | DUR Board Packets & Meeting Minutes Archive
|September 17, 2020||Agenda||Minutes|
|June 11, 2020||Agenda||Minutes|
|March 19, 2020||Agenda||Minutes|
|Dec. 5, 2019||Agenda||Minutes|
|Sept. 19, 2019||Agenda||Minutes|
|May 23, 2019||Agenda||Minutes|
|March 7, 2019||Agenda||Minutes|
Mississippi Evidence-Based DUR Initiative
The Mississippi Evidence-Based DUR Initiative (MS-DUR) performs the retrospective drug utilization review (DUR) for the Mississippi Division of Medicaid. MS-DUR supports the function of the DUR Board by performing in-depth analyses using pharmacy and medical claims data to encourage evidence-based appropriate use of medications in the Mississippi Medicaid population. MS-DUR reviews claims data and monitors FDA-based safety information to ensure quality care is delivered to Medicaid beneficiaries. Based on activities of the DUR Board and claims reviews, MS-DUR provides educational outreach to health care practitioners on drug therapy to improve prescribing and dispensing practices for Mississippi Division or Medicaid beneficiaries.
The MS-DUR website has resources for providers, including the “Mississippi Medicaid Pharmacy Update” newsletters and special initiatives developed to assist providers in selecting therapy, like the “Medicaid Cough and Cold Quick List.”